The content on this site is intended for healthcare professionals only
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity i...
Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA
5 Jun 2022
Review: Best options in localised prostate cancer
Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim Fizaz...
4 Jun 2022
Everolimus after surgery can improve outcomes in those with high-risk kidney can...
Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA
4 Jun 2022
Advance Prostate Cancer Consensus Conference 2021: Report
Prof Silke Gillessen and Prof Aurelius Omlin
29 Apr 2022
ASCO GU 2022: Prostate roundup
Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore
20 Apr 2022
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid ...
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
14 Apr 2022
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/...
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
13 Apr 2022
ASCO GU 2022: Latest in mHSPC
Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith
8 Mar 2022
ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE
Dr Neal Shore and Prof Kim Chi
4 Mar 2022
An AI-derived digital pathology-based biomarker to predict the benefit of ADT in...
Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA
3 Mar 2022
SG in combination with pembro in patients with mUC who progressed after platinum...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
28 Feb 2022
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion
Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA
28 Feb 2022